Tag Archives: biotech industry

Methylgene to receive equity investment from Otsuka Pharmaceutical

MethylGene Inc. (TSX: MYG) agreed to issue 3,686,182 common shares to Otsuka Pharmaceutical Co., Ltd. as part of a research collaboration and license agreement for the development of  small molecule kinase inhibitors for ocular diseases excluding cancer. Otsuka will acquire newly issued common shares of MethylGene at a purchase price of approximately $0.43 per share for gross proceeds of $1,500,000. In September 2009, MethylGene announced that Otsuka had extended the research portion of the collaboration Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Provectus starts compassionate use program for PV-10

Provectus Pharmaceuticals, Inc. (OTCBB: PVCT) expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009. The program for PV-10 is being implemented under the FDA’s guidelines covering compassionate use of an investigational new drug. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Positive Palifosfamide Sarcoma Phase II Data from ZIOPHARM

ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced positive data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed. As a result of reaching a key efficacy milestone and following safety and efficacy data review by the Data Committee, sarcoma experts, and the Company’s Medical Advisory Board, made the decision Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Positive clinical trial results for Epeius

Epeius Biotechnologies Corporation announced results of its Rexin-G®  clinical trials. Administered as stand-alone therapy in late-stage cases of chemotherapy-resistant cancer, Rexin-G has shown benefits of remission in otherwise intractable metastatic cancers. Three recent cases of Stage IV metastatic cancer, namely (i) osteosarcoma, (ii) prostate cancer, and (iii) pancreas cancer, demonstrated that Rexin-G treatments alone led to clinical remission of disease in patients. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Locus Pharmaceuticals and Novartis enter into research collaboration

Locus Pharmaceuticals has entered into a discovery research collaboration with Novartis. Locus will collaborate with Novartis to discover novel chemotypes on targets of interest to Novartis’ select therapeutic areas.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,